These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26661410)

  • 1. G protein-coupled receptors as new therapeutic targets for type 2 diabetes.
    Reimann F; Gribble FM
    Diabetologia; 2016 Feb; 59(2):229-33. PubMed ID: 26661410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G-protein-coupled receptors (GPCRs) in the treatment of diabetes: Current view and future perspectives.
    Sebastiani G; Ceccarelli E; Castagna MG; Dotta F
    Best Pract Res Clin Endocrinol Metab; 2018 Apr; 32(2):201-213. PubMed ID: 29678286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of G-protein coupled receptors as potential targets against type 2 diabetes mellitus.
    Hoque M; Ali S; Hoda M
    Int J Biol Macromol; 2018 Oct; 118(Pt B):2237-2244. PubMed ID: 30030074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes.
    Winzell MS; Ahrén B
    Pharmacol Ther; 2007 Dec; 116(3):437-48. PubMed ID: 17900700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans.
    Amisten S; Salehi A; Rorsman P; Jones PM; Persaud SJ
    Pharmacol Ther; 2013 Sep; 139(3):359-91. PubMed ID: 23694765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the glucagon receptor family for diabetes and obesity therapy.
    Cho YM; Merchant CE; Kieffer TJ
    Pharmacol Ther; 2012 Sep; 135(3):247-78. PubMed ID: 22659620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus.
    Riddy DM; Delerive P; Summers RJ; Sexton PM; Langmead CJ
    Pharmacol Rev; 2018 Jan; 70(1):39-67. PubMed ID: 29233848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatty acid receptors as new therapeutic targets for diabetes.
    Rayasam GV; Tulasi VK; Davis JA; Bansal VS
    Expert Opin Ther Targets; 2007 May; 11(5):661-71. PubMed ID: 17465724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes.
    Ahrén B
    Nat Rev Drug Discov; 2009 May; 8(5):369-85. PubMed ID: 19365392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.
    Rozengurt E; Sinnett-Smith J; Kisfalvi K
    Clin Cancer Res; 2010 May; 16(9):2505-11. PubMed ID: 20388847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes.
    Sharma N; Bhagat S; Chundawat TS
    Mini Rev Med Chem; 2017; 17(11):947-958. PubMed ID: 28117025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of novel ligands for peptide GPCRs.
    Moran BM; McKillop AM; O'Harte FP
    Curr Opin Pharmacol; 2016 Dec; 31():57-62. PubMed ID: 27607913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G protein-coupled receptors as therapeutic targets for obesity and type 2 diabetes.
    Bjenning C; Al-Shamma H; Thomsen W; Leonard J; Behan D
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1051-62. PubMed ID: 15535426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
    Li Z; Xu X; Huang W; Qian H
    Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Islet G-protein coupled receptors: therapeutic potential for diabetes.
    Persaud SJ
    Curr Opin Pharmacol; 2017 Dec; 37():24-28. PubMed ID: 28822846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple benefits of targeting inflammation in the treatment of type 2 diabetes.
    Donath MY
    Diabetologia; 2016 Apr; 59(4):679-82. PubMed ID: 26868493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?
    Majumdar SK; Inzucchi SE
    Endocrine; 2013 Aug; 44(1):47-58. PubMed ID: 23354728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus.
    Ludwig B; Barthel A; Reichel A; Block NL; Ludwig S; Schally AV; Bornstein SR
    Vitam Horm; 2014; 95():195-222. PubMed ID: 24559919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.